HDAC inhibition may combat resistance to anti-PD-1 therapy in patients with melanoma
ATLANTA -- A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda) showed clinical responses in patients with melanoma...









